Bookmark

Add to MyYahoo RSS

Spectrum Pharmaceuticals News

News on Spectrum Pharmaceuticals (Ticker: SPPI) continually updated from thousands of sources around the net.

Tuesday Jul 15 | AmericanBankingNews.com

Spectrum Pharmaceuticals PT Raised to $7.50

The firm currently has a "hold" rating on the stock. R. F. Lafferty's price target indicates a potential downside of 3.35% from the company's current price.

Comment?

Related Topix: Biotech, Healthcare Industry

Wed Jul 09, 2014

Seeking Alpha

Spectrum Pharmaceuticals: Key Drug Fusilev May Face Generic Competition Soon

The author of this article is a private fund manager. At the time of publication, funds and accounts managed by the author were short Spectrum Pharmaceuticals, Inc. .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

P&T Community

FDA Approves Beleodaq (Belinostat) to Treat Rare Type of Non-Hodgkin Lymphoma

The FDA has approved Beleodaq for the treatment of patients with peripheral T-cell lymphoma , a rare and fast-growing type of non-Hodgkin lymphoma .

Comment?

Related Topix: Lymphoma, Health, Biotech, Medicine, Healthcare Industry

Mon Jul 07, 2014

TheStreet.com

Why Spectrum Pharmaceuticals (SPPI) Stock Is Higher This Morning

TheStreet Ratings team rates SPECTRUM PHARMACEUTICALS INC as a Sell with a ratings score of D+.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Science / Technology, Financial Markets

AmericanBankingNews.com

Spectrum Pharmaceuticals Given "Positive" Rating at Roth Capital

Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Spectrum Pharmaceuticals from an "outperform" rating to a "neutral" rating in a research note on Thursday, June 5th.

Comment?

Related Topix: Biotech, Healthcare Industry

Business Wire

FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaqa (belinostat) for Injection

This indication is approved under accelerated approval based on Tumor Response Rate and Duration of Response .

Comment?

Related Topix: Healthcare Law, Law, Food and Drug Administration, Biotech, Medicine, Healthcare Industry

Sat Jul 05, 2014

P&T Community

FDA Approves Beleodaq (Belinostat) to Treat Rare Type of Non-Hodgkin Lymphoma

The FDA has approved Beleodaq for the treatment of patients with peripheral T-cell lymphoma , a rare and fast-growing type of non-Hodgkin lymphoma .

Comment?

Related Topix: Lymphoma, Health, Biotech, Medicine, Healthcare Industry

Thu Jul 03, 2014

Benzinga

Spectrum Pharmaceuticals Shares Up 5% Following FDA Accelerated Approval For Beleodaq

Shares of Spectrum Pharmaceuticals gained 5.7 percent following the U.S. Food and Drug Administration's approval of the New Drug Application for Beleodaq.

Comment?

Related Topix: Biotech, Healthcare Law, Medicine, Law, Healthcare Industry, Food and Drug Administration

BioSpace

FDA Green Lights Spectrum Pharmaceuticals, Inc.'s Beleodag To Treat Rare Form Of Lymphoma

FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma The U.S. Food and Drug Administration today approved Beleodaq for the treatment of patients with peripheral T-cell lymphoma , a rare and fast-growing type of non-Hodgkin lymphoma .

Comment?

Related Topix: Food and Drug Administration, Lymphoma, Health, Biotech, Medicine, Healthcare Industry, Oncology, Hematology

Tue Jul 01, 2014

GlobeNewswire

New Articles of Association following capital increase

Topotarget is a Danish-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to the clinical development and registration of oncology products.

Comment?

Related Topix: NASDAQ OMX, World News, Denmark, Biotech, Medicine, Healthcare Industry

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••